Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - carvedilol, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; magnesium stearate; colloidal anhydrous silica; povidone; crospovidone - dilatrend is indicated for the treatment for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to moderate (nyha class ii & iii) congestive heart failure, as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators). indications as at 24 january 2002: dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators). indications as at 3 march 2003: dilatrend is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - carvedilol, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; magnesium stearate; colloidal anhydrous silica; povidone; crospovidone; iron oxide yellow; iron oxide red - dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to moderate (nyha class ii & iii) congestive heart failure, as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators). indications as at 24 january 2002: dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators). indications as at 3 march 2003: dilatrend is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - carvedilol, quantity: 6.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; magnesium stearate; colloidal anhydrous silica; povidone; crospovidone; iron oxide yellow - dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to moderate (nyha class ii & iii) congestive heart failure, as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators). indications as at 24 january 2002: dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators). indications as at 3 march 2003: dilatrend is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - mefloquine hydrochloride, quantity: 274.09 mg (equivalent: mefloquine, qty 250 mg) - tablet, uncoated - excipient ingredients: ammonium alginate; crospovidone; lactose monohydrate; magnesium stearate; microcrystalline cellulose; purified talc; maize starch; poloxamer - malaria treatment: lariam is indicated for the treatment of acute attacks of malaria due to p.falciparum infection resistant to conventional antimalarial drugs. following therapy of mixed p.falciparum/p.vivax malaria with lariam relapse prophylaxis with an 8-aminoquinoline derivative (e.g. primaquine) should be considered in order to eliminate liver forms of p.vivax. malaria prophylaxis: for travellers to countries with documented chloroquine and antifolate combination ( [sulfadoxine/pyrimethamine] / [dapsone/pyrimethamine] ) resistant p.falciparum malaria, who are considered to be at high risk for malaria in view of their residence or travel (of up to 3 months duration) through rural areas (between the dusk to dawn period). for travellers hypersensitive to sulphonamides and sulphones, who are considered to be at high risk for malaria in view of their residence or travel (of up to 3 months duration) through rural areas, (between the dusk to dawn period) in countries with high level chloroquine-resistant p.fal

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - clonazepam, quantity: 1 mg - diluent, not applicable - excipient ingredients: water for injections - injection: intravenous use, for status epilepticus.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - ganciclovir sodium, quantity: 543 mg (equivalent: ganciclovir, qty 500 mg) - injection, powder for - excipient ingredients: - indications as at 12 october 2005: cymevene (ganciclovir) administered as the intravenous infusion is indicated for the palliative treatment of confirmed sight-threatening cytomegalovirus (cmv) disease in aids and other severely immunocompromised individuals. it is indicated for the treatment of confirmed cmv pneumonitis in bone marrow transplant patients. it is also indicated for the prophylaxis of cmv infection and disease following bone marrow and solid organ transplantation in patients at risk of cmv disease. note: cymevene (ganciclovir) is not indicated for congenital or neonatal cmv disease; nor for the treatment of cmv infection in non-immunocompromised individuals.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - olanzapine 10mg - film coated tablet - 10 mg - active: olanzapine 10mg excipient: carnauba wax crospovidone hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opacode blue s-1-10537g opadry white ys-1-18027-a - zyprexa is indicated for the treatment of schizophrenia and related psychoses.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - olanzapine 2.5mg - film coated tablet - 2.5 mg - active: olanzapine 2.5mg excipient: carnauba wax crospovidone hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opacode blue s-1-10537g opadry white ys-1-18027-a - zyprexa is indicated for the treatment of schizophrenia and related psychoses.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - olanzapine 5mg - film coated tablet - 5 mg - active: olanzapine 5mg excipient: carnauba wax crospovidone hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opacode blue s-1-10537g opadry white ys-1-18027-a - zyprexa is indicated for the treatment of schizophrenia and related psychoses.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - olanzapine 7.5mg - film coated tablet - 7.5 mg - active: olanzapine 7.5mg excipient: carnauba wax crospovidone hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opacode blue s-1-10537g opadry white ys-1-18027-a - zyprexa is indicated for the treatment of schizophrenia and related psychoses.